{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-044025","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.826775+00:00","generated_at":"2026-05-15T05:49:04.879817+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MeiraGTx reports positive 3-year Phase 1 data for AAV-hAQP1 in radiation-induced xerostomia","bullets":["62% of patients had ≥10-point XQ improvement at 36 months; average 17-point improvement maintained from 12 months.","Unstimulated saliva flow normalized to average 0.36 mL/min at 12 months, maintained at 0.34 mL/min at 36 months.","No dose-limiting toxicity or treatment-related serious adverse events; well tolerated at all doses.","Company estimates peak global revenue potential of $3.7B, U.S. peak of $2.0B, targeting ~165,000 U.S. patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-044025","json":"https://secwatch.observer/filing/0001104659-26-044025.json","markdown":"https://secwatch.observer/filing/0001104659-26-044025.md","text":"https://secwatch.observer/filing/0001104659-26-044025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/0001104659-26-044025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000110465926044025/mgtx-20260416x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:49:04.879817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}